α1抗胰蛋白酶缺乏症相关肺病的α1抗胰蛋白酶增强治疗。

IF 8.8 2区医学 Q1 MEDICINE, GENERAL & INTERNAL

Cochrane Database of Systematic Reviews Pub Date : 2024-10-16 DOI:10.1002/14651858.CD015930

Patrick Glaister, Nichola Hindle Robinson, Amy Ward, Chloe Bentham, Iain Crossingham

引用次数: 0

摘要

目标：这是一份科克伦综述（干预）协议。目标如下评估α1 抗胰蛋白酶缺乏症患者接受α1 抗胰蛋白酶增强疗法对呼吸系统疾病的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Alpha 1 antitrypsin augmentation for alpha 1 antitrypsin deficiency associated lung disease.

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of alpha 1 antitrypsin augmentation therapy on respiratory disease in people with alpha 1 antitrypsin deficiency.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cochrane Database of Systematic Reviews 医学-医学：内科

CiteScore

10.60

自引率

2.40%

发文量

173

审稿时长

1-2 weeks

期刊介绍： The Cochrane Database of Systematic Reviews (CDSR) stands as the premier database for systematic reviews in healthcare. It comprises Cochrane Reviews, along with protocols for these reviews, editorials, and supplements. Owned and operated by Cochrane, a worldwide independent network of healthcare stakeholders, the CDSR (ISSN 1469-493X) encompasses a broad spectrum of health-related topics, including health services.